Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease
- PMID: 10796634
- DOI: 10.1002/14651858.CD001287
Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease
Update in
-
Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2003;(2):CD001287. doi: 10.1002/14651858.CD001287. Cochrane Database Syst Rev. 2003. Update in: Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001287. doi: 10.1002/14651858.CD001287.pub2. PMID: 12804402 Updated.
Abstract
Background: Individuals with chronic bronchitis or chronic obstructive pulmonary disease (COPD) may suffer recurrent exacerbations with an increase in volume and/or purulence of sputum and any therapy that reduced the number of exacerbations would be useful. There is a marked difference between countries in terms of the prescribing of mucolytics depending on whether or not they are perceived to be effective.
Objectives: To assess the effects of oral mucolytics in adults with stable chronic bronchitis or COPD.
Search strategy: We searched the Cochrane Airways Group trials register and reference lists of articles.
Selection criteria: Randomised trials that compared oral mucolytic therapy with placebo for at least two months in adults with chronic bronchitis or COPD. Studies of people with asthma and cystic fibrosis were excluded.
Data collection and analysis: One reviewer extracted data. Study authors and drug companies were contacted for missing information.
Main results: Twenty two trials were included. Compared with placebo, there was a significant reduction in the number of exacerbations per patient with oral mucolytics (weighted mean difference (WMD) -0.067 per month, 95% confidence interval -0.079, -0.055, p<0.001) which is a 29% reduction. The annualised rate of exacerbations in the control patients was 2.7 per year. The number of days of disability also fell on mucolytic therapy (WMD -0.56, 95% confidence interval -0.77, -0.35, p<0.001). The number of patients who remained exacerbation-free was greater in the mucolytic group thanin the placebo group (OR 2.22, 95% confidence interval 1.93, 2.54, p<0.001). There was no difference in lung function or in adverse effects reported between treatments.
Reviewer's conclusions: In subjects with chronic bronchitis or COPD, treatment with mucolytics was associated with a small reduction in acute exacerbations and a somewhat greater reduction in total number of days of disability.
Comment in
-
Review: mucolytic drugs reduce exacerbations, illness days, and antibiotic use in chronic bronchitis and COPD.ACP J Club. 2002 Mar-Apr;136(2):54. ACP J Club. 2002. PMID: 11874279 No abstract available.
Similar articles
-
Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001287. doi: 10.1002/14651858.CD001287.pub2. Cochrane Database Syst Rev. 2006. Update in: Cochrane Database Syst Rev. 2010 Feb 17;(2):CD001287. doi: 10.1002/14651858.CD001287.pub3. PMID: 16855965 Updated.
-
Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2003;(2):CD001287. doi: 10.1002/14651858.CD001287. Cochrane Database Syst Rev. 2003. Update in: Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001287. doi: 10.1002/14651858.CD001287.pub2. PMID: 12804402 Updated.
-
Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2012 Aug 15;(8):CD001287. doi: 10.1002/14651858.CD001287.pub4. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2015 Jul 29;(7):CD001287. doi: 10.1002/14651858.CD001287.pub5. PMID: 22895919 Updated.
-
Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2015 Jul 29;(7):CD001287. doi: 10.1002/14651858.CD001287.pub5. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2019 May 20;5:CD001287. doi: 10.1002/14651858.CD001287.pub6. PMID: 26222376 Updated.
-
Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2010 Feb 17;(2):CD001287. doi: 10.1002/14651858.CD001287.pub3. Cochrane Database Syst Rev. 2010. Update in: Cochrane Database Syst Rev. 2012 Aug 15;(8):CD001287. doi: 10.1002/14651858.CD001287.pub4. PMID: 20166060 Updated.
Cited by
-
Drug reimbursement: indicators of inappropriate resource allocation.Br J Clin Pharmacol. 2002 Nov;54(5):528-34. doi: 10.1046/j.1365-2125.2002.01690.x. Br J Clin Pharmacol. 2002. PMID: 12445033 Free PMC article.
-
Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review.BMJ. 2001 May 26;322(7297):1271-4. doi: 10.1136/bmj.322.7297.1271. BMJ. 2001. PMID: 11375228 Free PMC article.
-
COPD exacerbations. 4: Prevention.Thorax. 2006 May;61(5):440-7. doi: 10.1136/thx.2005.041848. Thorax. 2006. PMID: 16648352 Free PMC article. Review.
-
Pharmacological treatment of chronic obstructive pulmonary disease.Int J Chron Obstruct Pulmon Dis. 2006;1(4):409-23. doi: 10.2147/copd.2006.1.4.409. Int J Chron Obstruct Pulmon Dis. 2006. PMID: 18044097 Free PMC article. Review.
-
Antitussive drugs--past, present, and future.Pharmacol Rev. 2014 Mar 26;66(2):468-512. doi: 10.1124/pr.111.005116. Print 2014. Pharmacol Rev. 2014. PMID: 24671376 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical